Helix BioPharma Corp. Cash Flow Conversion Efficiency

Latest as of January 2026: -0.030x

Helix BioPharma Corp. cash flow conversion efficiency. Based on the latest financial reports, Helix BioPharma Corp. (HBP) has a cash flow conversion efficiency ratio of -0.030x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-456.00K ≈ $-329.86K USD) by net assets (CA$15.36 Million ≈ $11.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Helix BioPharma Corp. (2007–2025)

Cash flow conversion efficiency of Helix BioPharma Corp. from 2007 to 2025. This chart illustrates how Helix BioPharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Helix BioPharma Corp. (HBP) share price today for real-time trading data and today's change.

Helix BioPharma Corp. Cash Flow Conversion Ratio Explained

Helix BioPharma Corp. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Helix BioPharma Corp. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Helix BioPharma Corp. ranked by their cash flow conversion efficiency. Also see market value of Helix BioPharma Corp. for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Reliance Securities Tbk JK:RELI	-0.001x
ICAPE HOLDING EO -40 F:Z8J	N/A
DLH Holdings Corp NASDAQ:DLHC	0.045x
Cenit Co. Ltd KQ:037760	-0.013x
Company K Partners Limited KQ:307930	-0.077x
Southport Acquisition Corp NYSE:PORT	0.020x
Broadwind Energy Inc NASDAQ:BWEN	0.013x
Harmoney Corp Ltd AU:HMY	0.514x

Annual Cash Flow Conversion Efficiency for Helix BioPharma Corp. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Helix BioPharma Corp. from 2007 to 2025. Review financial agility of Helix BioPharma Corp. to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-07-31	CA$15.59 Million ≈ $11.27 Million	CA$-3.83 Million ≈ $-2.77 Million	-0.246x	-100.42%
2024-07-31	CA$-90.00K ≈ $-65.10K	CA$-5.22 Million ≈ $-3.78 Million	57.989x	+785.52%
2023-07-31	CA$-844.00K ≈ $-610.54K	CA$-5.53 Million ≈ $-4.00 Million	6.549x	+132.09%
2022-07-31	CA$319.00K ≈ $230.76K	CA$-6.51 Million ≈ $-4.71 Million	-20.404x	-405.50%
2021-07-31	CA$-1.39 Million ≈ $-1.01 Million	CA$-9.30 Million ≈ $-6.73 Million	6.679x	+283.91%
2020-07-31	CA$2.98 Million ≈ $2.16 Million	CA$-10.83 Million ≈ $-7.83 Million	-3.632x	-315.43%
2019-07-31	CA$-3.28 Million ≈ $-2.37 Million	CA$-5.53 Million ≈ $-4.00 Million	1.686x	-65.79%
2018-07-31	CA$-1.53 Million ≈ $-1.10 Million	CA$-7.52 Million ≈ $-5.44 Million	4.927x	-99.10%
2017-07-31	CA$-17.00K ≈ $-12.30K	CA$-9.29 Million ≈ $-6.72 Million	546.765x	+19640.99%
2016-07-31	CA$3.16 Million ≈ $2.29 Million	CA$-8.85 Million ≈ $-6.40 Million	-2.798x	-125.05%
2015-07-31	CA$6.83 Million ≈ $4.94 Million	CA$-8.49 Million ≈ $-6.14 Million	-1.243x	-10.09%
2014-07-31	CA$6.81 Million ≈ $4.93 Million	CA$-7.69 Million ≈ $-5.56 Million	-1.129x	+28.89%
2013-07-31	CA$4.92 Million ≈ $3.56 Million	CA$-7.81 Million ≈ $-5.65 Million	-1.588x	+29.95%
2012-07-31	CA$6.22 Million ≈ $4.50 Million	CA$-14.11 Million ≈ $-10.21 Million	-2.267x	-384.94%
2011-07-31	CA$22.11 Million ≈ $16.00 Million	CA$-10.34 Million ≈ $-7.48 Million	-0.468x	+39.56%
2010-07-31	CA$15.76 Million ≈ $11.40 Million	CA$-12.19 Million ≈ $-8.82 Million	-0.774x	-0.33%
2009-07-31	CA$17.06 Million ≈ $12.34 Million	CA$-13.16 Million ≈ $-9.52 Million	-0.771x	-126.16%
2008-07-31	CA$20.52 Million ≈ $14.85 Million	CA$-7.00 Million ≈ $-5.06 Million	-0.341x	+28.58%
2007-07-31	CA$12.73 Million ≈ $9.21 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.477x	--

About Helix BioPharma Corp.

TO:HBP Canada Biotechnology

Market Cap

$50.83 Million

CA$70.27 Million CAD

Market Cap Rank

#21635 Global

#746 in Canada

Share Price

CA$0.92

Change (1 day)

-9.80%

52-Week Range

CA$0.82 - CA$2.45

All Time High

CA$11.25